The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03347253




Registration number
NCT03347253
Ethics application status
Date submitted
9/11/2017
Date registered
15/11/2017
Date last updated
6/02/2019

Titles & IDs
Public title
STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT
Scientific title
A Prospective Study in Subjects With Late Onset Pompe Disease Who Are Currently Being Treated With Enzyme Replacement Therapy
Secondary ID [1] 0 0
POM-003
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Late-onset Pompe Disease 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Metabolic disorders
Metabolic and Endocrine 0 0 0 0
Other metabolic disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Evaluate degree of change in muscle function and respiratory endpoints over time - To evaluate the degree of change in muscle function and respiratory endpoints over time in patients with Late Onset Pompe disease
Timepoint [1] 0 0
6-15 month

Eligibility
Key inclusion criteria
1. Subject has a diagnosis of Pompe disease based on documented deficiency of GAA
activity and a documented GAA mutation.

2. Male and female subjects between 18 years and 75 years, inclusive and = 50 kg.

3. Subject must be currently receiving standard-of-care ERT (alglucosidase alfa) at a
dose of 20 mg/kg dose every other week.

4. Subject must have been on ERT for the preceding 2 years or more.

5. Subject must have an upright forced vital capacity (FVC) within 35 to 90% of predicted
normal (NHANES III reference values), based on the higher of the screening or baseline
value, if their 6 minute walk distance (6MWD) is > 200 m. Subject must have an upright
FVC within 40 to 90% of predicted normal (NHANES III reference values), based on the
higher of the screening or baseline value, if their 6MWD is = 200 m. If FVC is between
80 and 90% of predicted normal, the subject may enter the study if the percent
predicted FVC value drops by 10% predicted or more in supine position

6. Subject is able to walk at least 100 m in the 6MWT and the assessment is noted as
valid.
Minimum age
18 Years
Maximum age
75 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Subject has received any investigational therapy or pharmacological treatment for
Pompe disease, other than alglucosidase alfa within 30 days or 5 half lives, whichever
is shorter, prior to the Baseline Visit or is anticipated to do so during the course
of the study

2. Subject is on any of the following prohibited medications within 30 days of baseline:

- miglitol (eg, Glyset)

- miglustat (eg, Zavesca)

- acarbose (eg, Precose, Glucobay)

- voglibose (eg, Volix, Vocarb, Volibo)

3. Subject requires use of invasive or non-invasive ventilatory support for > 6 hours a
day while awake.

4. Subject has a medical or any other extenuating condition or circumstance that may, in
the opinion of the investigator, pose an undue safety risk to the subject or
compromise his/her ability to comply with protocol requirements. This includes
clinical depression (as diagnosed by a psychiatrist or other mental health
professional) with uncontrolled or poorly controlled symptoms.

5. Subject is breastfeeding, or is pregnant or planning to become pregnant within the
next 2 years.

6. Other exclusion criteria according to the Lumizyme/Myozyme instructions for use.

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Kansas
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
Minnesota
Country [7] 0 0
United States of America
State/province [7] 0 0
New Jersey
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
North Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Oregon
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
Belgium
State/province [14] 0 0
Edegem
Country [15] 0 0
Canada
State/province [15] 0 0
Alberta
Country [16] 0 0
Canada
State/province [16] 0 0
Ontario

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Amicus Therapeutics
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the study is to evaluate changes in key clinical outcome measures (eg, motor,
respiratory, fatigue) in adult subjects with late-onset Pompe disease (LOPD) subjects
receiving standard-of-care enzyme replacement therapy (ERT). Additionally, information gained
may be used in the design and conduct of future studies in LOPD subjects.
Trial website
https://clinicaltrials.gov/show/NCT03347253
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No data has been provided for results reporting
Summary results
Not applicable